This year, the World Federation of Hemophilia (WFH) is celebrating a major milestone: the distribution of more than 1 billion international units (IUs) of factor along with non-factor replacement therapy through the WFH Humanitarian Aid Program. This treatment product has allowed people with bleeding disorders (PWBD) around the world to enjoy a better quality of life. In many cases, these donations have saved the lives of adults—and children.
WFH Humanitarian Aid Program donations have gone to people diagnosed with hemophilia and other bleeding disorders in 110 countries—at no cost to recipients. More than 20,000 patients living with bleeding disorders have been helped by the Program across the globe.
More than 1 billion international IUs of factor have been consistently delivered to PWBD since 1996, despite many challenges. Last year, the WFH was able to distribute 146 million IUs of treatment across the globe despite the challenges presented by the COVID-19 pandemic.
On behalf of the WFH and the bleeding disorders community, we thank our sponsors for their generous support. We are proud of what we have accomplished together, and we look forward to continuing our collaboration with you in the future.
About the WFH Humanitarian Aid Program
The WFH Humanitarian Aid Program improves the lack of access to care and treatment by providing much-needed support for people with inherited bleeding disorders in developing countries. By providing patients with a more predictable and sustainable flow of humanitarian aid donations, the WFH Humanitarian Aid Program makes it possible for patients to receive consistent and reliable access to treatment and care. None of this would be possible without the generous support of Sanofi Genzyme and Sobi, our Founding Visionary Contributors; Bayer and Roche, our Visionary Contributors; Grifols, our Leadership Contributor; and our Contributors, CSL Behring and Takeda. To learn more about the WFH Humanitarian Aid Program, visit www.treatmentforall.org.